Minutti-Palacios M

Language: Spanish
References: 20
Page: 46-49
PDF size: 822.77 Kb.

Text Extraction

No abstract.

REFERENCES

1. Kheterpal S, Vaughn MT, Dubovoy TZ, Shah NJ, Bash LD,Colquhoun DA, et al. Sugammadex versus neostigmine for reversal ofneuromuscular blockade and postoperative pulmonary complications(STRONGER): a multicenter matched cohort analysis. Anesthesiology. 2020;132:1371-1381.

2. Colquhoun DA, Vaughn MT, Bash LD, Janda A, Shah N, Ghafei A,et al. Association between choice of reversal agent for neuromuscularblock and postoperative pulmonary complications (STIL-STRONGER):a multicentre matched cohort study. Br J Anaesth. 2023;130:e148-e159.

3. Zhang Y, Jiang Y, Lei Q, Li C, Jin S, Wang Q, et al. Phase III clinical trialcomparing the efficacy and safety of adamgammadex with sugammadexfor reversal of rocuronium-induced neuromuscular block. Br J Anaesth.2024;132:45-52.

4. Zhao Y, Chen S, Xie W, Zhang X, Chen G, Ji F, et al. Efficacy andsafety of adamgammadex for reversing rocuronium-induced deepneuromuscular blockade: a multicenter, randomized, phase IIb study.Clin Transl Sci. 2024;17:e13691.

5. Zhao Y, Ren Y, Xie W, Wang Y, Lei Y, Zhu Y, et al. Efficacy andsafety of adamgammadex for reversing rocuronium-induced deepneuromuscular block: a multicentre, randomised, double-blind, positivecontrolledphase III trial. Br J Anaesth. 2025;135:331-339.

6. Hunter JM, Sneyd JR. Is adamgammadex the brother of sugammadexor the next generation of reversal agent? Br J Anaesth. 2024;132:15-17.

7. Qi YM, Qi YB, Yu BC, et al. Comparison of the efficacy and safety ofadamgammadex with sugammadex for reversal of rocuronium-inducedneuromuscular block: results of a phase II clinical trial. Drug Des DevelTher. 2022;16:4029-4036.

8. Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safetyof sugammadex versus neostigmine in reversing neuromuscular blockadein adults. Cochrane Database Syst Rev. 2017;8:CD012763.

9. Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned.Part I: Definitions, incidence, and adverse physiologic effects. AnesthAnalg. 2010;111:120-128.

10. Carron M, Veronese S, Foletto M, Ori C. Sugammadex allows fast-trackbariatric surgery. Obes Surg. 2013;23:1558-1563.

11. Badaoui R, Cabaret A, Alami Y, et al. Reversal of neuromuscularblockade by sugammadex in laparoscopic bariatric surgery: in supportof dose reduction. Anaesth Crit Care Pain Med. 2016;35:25-29.

12. Wong J, Farber A, Abreu M, et al. Impact of sugammadex versusneostigmine reversal on postoperative recovery time in patients withobstructive sleep apnea undergoing bariatric surgery. Anesth Analg.2025;140:568-576.

13. Kirmeier E, Eriksson LI, Lewald H, et al. Post-anaesthesia pulmonarycomplications after use of muscle relaxants (POPULAR): a multicentre,prospective observational study. Lancet Respir Med. 2019;7:129-140.

14. Stauble CG, Blobner M. The future of neuromuscular blocking agents.Curr Opin Anaesthesiol. 2020;33:490-498.

15. Blobner M, Hunter JM, Meistelman C, et al. Use of a train-of-four ratioof 0.95 versus 0.9 for the reversal of rocuronium-induced neuromuscularblock: analysis of pooled data from four phase III clinical trials. Br JAnaesth. 2020;124:33-40.

16. Hoffmann U, Grosse-Sundrup M, Eikermann-Haerter K, et al.Calabadion: a new agent to reverse the effects of benzylisoquinolineand steroidal neuromuscular-blocking agents. Anesthesiology.2013;119:317-325.

17. Errando CL, Garutti I, Mazzinari G, et al. Residual neuromuscularblockade in the postanesthesia care unit: observational crosssectionalstudy of a multicenter cohort. Minerva Anestesiol.2016;82:1267-1277.

18. Leslie K, Chan MTV, Darvall JN, et al. Sugammadex, neostigmine andpostoperative pulmonary complications: an international randomisedfeasibility and pilot trial. Pilot Feasibility Stud. 2021;7:200.

19. Mulier JP, Dillemans B. Anaesthetic factors affecting outcomes afterbariatric surgery, a retrospective levelled regression analysis. Obes Surg. 2019;29:1841-1850.

20. Lott C, Truhlár A, Alfonzo A, et al. Actual versus ideal body weightdosing of sugammadex in morbidly obese patients. BMC Anesthesiol.2021;21:55.